# US 2022/0064316 A1 · Treatment of cancer using humanized anti-bcma chimeric antigen receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064316 A1
- Document ID: US20220064316A1
- Status: Published application
- Kind: A1
- Application number: 17/359,211
- Filed: 2021-06-25
- Published: 2022-03-03
- Earliest claimed: 2014-07-21
- Assignees: The Trustees of the University of Pennsylvania; Novartis AG
- Applicants: The Trustees of the University of Pennsylvania; Novartis AG
- Inventors: Jennifer Brogdon; Eugene Choi; Hilmar Erhard Ebersbach; David Jonathan Glass; Heather Huet; Carl H. June; Joan Mannick; Michael C. Milone; Leon Murphy; Gabriela Plesa; Celeste Richardson; Marco Ruella; Reshma Singh; Yongqiang Wang; Qilong Wu
- Web page: https://patentgrep.com/patent/US20220064316A1

## CPC

- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/02: specific for leukemia
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- C07H 21/04: with deoxyribosyl as saccharide radical
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/70: containing domain for protein-protein interaction
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C12N 5/00: Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00)
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

## Claims

### Claim 1

An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an anti-BCMA binding domain, a transmembrane domain, and an intracellular signaling domain, and wherein said anti-BCMA binding domain comprises a heavy chain complementarity determining region 1 (HC CDR1), a heavy chain complementarity determining region 2 (HC CDR2), and a heavy chain complementarity determining region 3 (HC CDR3) of any anti-B MCA heavy chain binding domain amino acid sequences listed in Table 1 or 16; and
(ii) a light chain complementarity determining region 1 (LC CDR1), a light chain complementarity determining region 2 (LC CDR2), and a light chain complementarity determining region 3 (LC CDR3) of any anti-BMCA light chain binding domain amino acid sequences listed in Table 1 or 16.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein:
(a) said LC CDR1, LC CDR2, and LC CDR3 are the LC CDR sequences listed in Table 21, 23, or 25; and/or
(b) said HC CDR1, HC CDR2, and HC CDR3 are the HC CDR sequences listed in Table 20, 22, or 24.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The isolated nucleic acid molecule of claim 1, which encodes a CAR comprising:
(a) a light chain variable region comprising:
(i) the amino acid sequence of any light chain variable region listed in Table 1;
(ii) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications of the amino acid sequence of any of the light chain variable regions provided in Table 1; or
(iii) an amino acid sequence with 95-99% identity to the amino acid sequence of any of the light chain variable regions provided in Table 1; and/or
(b) a heavy chain variable region comprising:
(i) the amino acid sequence of any heavy chain variable region listed in Table 1;
(ii) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications of the amino acid sequence of any of the heavy chain variable regions provided in Table 1; or
(iii) an amino acid sequence with 95-99% identity to the amino acid sequence of any of the heavy chain variable regions provided in Table 1.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein:
(a) the encoded anti-BCMA binding domain comprises:
(i) the amino acid sequence selected from a group consisting of SEQ ID NO: 49, 39-53, 69-83, 84-98, 129-149, 171-191, 192-212, 255-258, 259-262, 263-266, 271, and 273;
(ii) an amino acid sequence having at least one, two or three modifications but not more than 30, 20 or 10 modifications to any of SEQ ID NO: 49, 39-53, 69-83, 84-98, 129-149, 171-191, 192-212. 255-258, 259-262, 263-266, 271, or 273;
(iii) an amino acid sequence with 95-99% identity to any of SEQ ID NO: 49, 39-53, 69-83, 84-98, 129-149, 171-191, 192-212, 255-258, 259-262, 263-266, 271, or 273;
(iv) the amino acid sequence of SEQ ID NO: 49;
(v) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications to SEQ ID NO: 49; or
(vi) an amino acid sequence with 95-99% identity to SEQ ID NO: 49
(b) the anti-BCMA binding domain comprises a nucleotide sequence selected from a group consisting of SEQ ID NO: 64, 54-68, 150-170, 272, and 274, or a sequence with 95-99% identity thereto:
(c) the nucleic acid molecule encodes a CAR comprising:
(i) the amino acid sequence of any of SEQ ID NOs: 109, 99-113, 213-233, or 267-270;
(ii) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications to any of SEQ ID NOs: 109, 99-113, 213-233, or 267-270; or
(iii) an amino acid sequence with 95-99% identity to any of SEQ ID NOs: 109, 99-113, 213-233, or 267-270; or
(d) the nucleic acid molecule comprises the nucleotide sequence of any of SEQ ID NOs: 124, 114-128 or 234-254, or a nucleotide sequence with 95-99% identity to any of SEQ ID NOs: 124, 114-128 or 234-254.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein:
(i) the encoded CAR comprises a transmembrane domain that comprises a transmembrane domain of a protein selected from the group consisting of the alpha, beta, or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154; or
(ii) the encoded transmembrane domain comprises the amino acid sequence of SEQ ID NO: 6, an amino acid sequence comprising at least one, two or three modifications but not more than 20, 10, or 5 modifications of the amino acid sequence of SEQ ID NO:6, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:6; or (ii) the nucleic acid sequence encoding the transmembrane domain comprises the nucleotide sequence of SEQ ID NO:17, or the nucleotide sequence with 95-99% identity thereto.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein the encoded anti-BCMA binding domain is connected to the transmembrane domain by a hinge region, wherein:
(i) the encoded hinge region comprises the amino acid sequence of SEQ ID NO:2, or a sequence with 95-99% identity thereto; or
(ii) the nucleic acid sequence encoding the hinge region comprises the nucleotide sequence of SEQ ID NO: 13, or a sequence with 95-99% identity thereto.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein:
(i) the encoded intracellular signaling domain comprises a, costimulatory domain, wherein the costimulatory domain comprises a functional signaling domain derived from a protein selected from the group consisting of MHC class I molecules, TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83;
(ii) the encoded intracellular signaling domain comprises a costimulatory domain, wherein the costimulatory domain comprises the amino acid sequence of SEQ ID NO:7, or an amino acid sequence having at least one, two, or three modifications but not more than 20, 10, or 5 modifications of the amino acid sequence of SEQ ID NO:7, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:7; or
(iii) the nucleic acid sequence encoding the costimulatory domain comprises the nucleotide sequence of SEQ ID NO:18, or a sequence with 95-99% identity thereto.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein:
(i) the encoded intracellular signaling domain comprises a functional signaling domain of 4-1BB and/or a functional signaling domain of CD3 zeta;
(ii) the encoded intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 7 and/or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10; or an amino acid sequence having at least one, two, or three modifications but not more than 20, 10, or 5 modifications of the amino acid sequence of SEQ ID NO:7 and/or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:7 and/or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10;
(iii) the encoded intracellular signaling domain comprises the amino acid sequence of SEQ ID NO:7 and the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain;
(iv) the isolated nucleic acid molecule comprises a nucleic acid sequence encoding the intracellular signaling domain comprising the nucleotide sequence of SEQ ID NO:18, or a sequence with 95-99% identity thereto, and/or the nucleotide sequence of SEQ ID NO:20 or SEQ ID NO:21, or a sequence with 95-99% identity thereto; or
(v) the isolated nucleic acid molecule further comprises a leader sequence which encodes the amino acid sequence of SEQ ID NO: 1.

### Claim at position 18

-24. (canceled)

### Claim 25

An isolated chimeric antigen receptor (CAR) polypeptide, wherein the CAR comprises an antibody or antibody fragment which includes an anti-BCMA binding domain, a transmembrane domain, and an intracellular signaling domain, comprising a costimulatory domain and/or a primary signaling domain, and wherein said anti-BCMA binding domain comprises:
(i) a heavy chain complementarity determining region 1 (HC CDR1), a heavy chain complementarity determining region 2 (HC CDR2), and a heavy chain complementarity determining region 3 (HC CDR3) of any anti-BCMA heavy chain binding domain amino acid sequences listed in Table 1 or 16; and
(ii) a light chain complementarity determining region 1 (LC CDR1), a light chain complementarity determining region 2 (LC CDR2), and a light chain complementarity determining region 3 (LC CDR3) of any anti-BCMA light chain binding domain amino acid sequences listed in Table 1 or 16.

### Claim 26

(canceled)

### Claim 27 (depends on 25)

The isolated CAR polypeptide of claim 25, wherein:
(a) said LC CDR1, LC CDR2, and LC CDR3 are the LC CDR sequences listed in Table 21, 23, or 25; and/or
(b) said HC CDR1, HC CDR2 and HC CDR3 are the HC CDR sequences listed in Table 21, 23, or 25.

### Claim 28

(canceled)

### Claim 29 (depends on 25)

The isolated CAR polypeptide of claim 25, comprising:
(a) a light chain variable region comprising:
(i) the amino acid sequence of any light chain variable region listed in Table 1;
(ii) an amino acid sequence having at least one, two or three modifications but not more than 30, 20, or 10 modifications of the amino acid sequence of any of the light chain variable region provided in Table 1; or
(iii) an amino acid sequence with 95-99% identity to the amino acid sequence of any of the light chain variable region provided in Table 1; and/or
(b) a heavy chain variable region comprising:
(i) the amino acid sequence of any heavy chain variable region listed in Table 1;
(ii) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications of the amino acid sequence of any of the heavy chain variable regions provided in Table 1; or
(ii) an amino acid sequence with 95-99% identity to the amino acid sequence of any of the heavy chain variable regions provided in Table 1.

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 25)

The isolated CAR polypeptide of claim 25, comprising:
(i) an amino acid sequence selected from a group consisting of SEQ ID NO: 49, 39-53, 69-83, 84-98, 129-149, 171-191, 192-212, 255-258, 259-262, 263-266, 271, and 273;
(ii) an amino acid sequence having at least one, two or three modifications but not more than 30, 20, or 10 modifications to any of SEQ ID NO: 49, 39-53, 69-83, 84-98, 129-149, 171-191, 192-212, 255-258, 259-262, 263-266, 271, and 273; or
(iii) an amino acid sequence with 95-99% identity to any of SEQ ID NO: 49, 39-53, 69-83, 84-98, 129-149, 171-191, 192-212, 255-258, 259-262, 263-266, 271, and 273.

### Claim 33 (depends on 25)

The isolated CAR polypeptide of claim 25, wherein:
(a) the transmembrane domain comprises a transmembrane domain from a protein selected from the group consisting of the alpha, beta, or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154;
(b) the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 6;
(c) the transmembrane domain comprises an amino acid sequence comprises at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid sequence of SEQ ID NO: 6; or
(iii) the transmembrane domain comprises a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO: 6.

### Claim 34

(canceled)

### Claim 35 (depends on 25)

The isolated CAR polypeptide of claim 25, wherein the anti-BCMA binding domain is connected to the transmembrane domain by a hinge region, wherein the hinge region comprises SEQ ID NO:2 or SEQ ID NO:36, or a sequence with 95-99% identity thereof.

### Claim 36

(canceled)

### Claim 37 (depends on 25)

The isolated CAR polypeptide of claim 25, wherein:
(a) the costimulatory domain is a functional signaling domain derived from a protein selected from the group consisting of MHC class I molecules, TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83; or
(b) the costimulatory domain comprises the amino acid sequence of SEQ ID NO: 7, or an amino acid sequence having at least one, two, or three modifications but not more than 20, 10, or 5 modifications of the amino acid sequence of SEQ ID NO: 7, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO: 7.

### Claim 38

(canceled)

### Claim 39 (depends on 25)

The isolated CAR polypeptide of claim 25, wherein:
(a) the intracellular signaling domain comprises a functional signaling domain of 4-1BB and/or a functional signaling domain of CD3 zeta;
(b) the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 7 and/or the sequence of SEQ ID NO: 9 or SEQ ID NO: 10, or an amino acid sequence having at least one, two, or three modifications but not more than 20, 10, or 5 modifications of the amino acid sequence of SEQ ID NO:7 and/or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:7 and/or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10.

### Claim at position 34

-42. (canceled)

### Claim 43 (depends on 25)

The isolated CAR polypeptide of claim 25, comprising:
(i) the amino acid sequence of any of SEQ ID NO: 109, 99-113, 213-233, or 267-270;
(ii) an amino acid sequence having at least one, two or three modifications but not more than 30, 20, or 10 modifications to any of SEQ ID NOs: 109, 99-113, 213-233, or 267-270; or
(iii) an amino acid sequence with 95-99% identity to any of SEQ ID NO: 109, 99-113, 213-233, or 267-270.

### Claim 44 (depends on 1)

A vector comprising a nucleic acid molecule encoding a CAR polypeptide of claim 1, wherein the vector is selected from the group consisting of a DNA vector, a RNA vector, a plasmid, a lentivirus vector, adenoviral vector, and a retrovirus vector.

### Claim 45

(canceled)

### Claim 46 (depends on 1)

An immune effector cell comprising the nucleic acid molecule of claim 1.

### Claim 47 (depends on 44)

A method of making an immune effector cell, comprising transducing the immune effector cell with the vector of claim 44.

### Claim 48 (depends on 1)

A method of generating a population of RNA-engineered cells comprising introducing an in vitro transcribed RNA or synthetic RNA into a cell, where the RNA comprises the nucleic acid molecule of claim 1.

### Claim 49 (depends on 1)

A method of providing an anti-tumor immunity in a mammal comprising administering to the mammal an effective amount of a cell comprising the CAR nucleic acid molecule of claim 1.

### Claim 50

(canceled)

### Claim 51 (depends on 1)

A method of treating a mammal having a disease associated with expression of BCMA, comprising administering to the mammal an effective amount of a cell comprising the CAR nucleic acid molecule of claim 1.

### Claim 52 (depends on 51)

The method of claim 51, wherein the disease associated with BCMA expression is:
(i) a cancer or malignancy, or a precancerous condition chosen from one or more of a myelodysplasia, a myelodysplastic syndrome or a preleukemia, or
(ii) a non-cancer related indication associated with expression of BCMA.

### Claim 53

(canceled)

### Claim 54 (depends on 51)

The method of claim 51, wherein the disease is an acute leukemia chosen from one or more of B-cell acute lymphoblastic leukemia (“BALL”), T-cell acute lymphoblastic leukemia (“TALL”), acute lymphoblastic leukemia (ALL); chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL); B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, Marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia; a prostate cancer, pancreatic cancer, lung cancer; or a plasma cell proliferative disorder, monoclonal gammapathy of undetermined significance (MGUS), Waldenstrom's macroglobulinemia, a plasmacytoma, systemic amyloid light chain amyloidosis, and POEMS syndrome, or a combination thereof.

### Claim 55 (depends on 51)

The method of claim 51, wherein the cell is administered in combination with one or more of:
(i) an agent that increases the efficacy of the cell comprising the CAR nucleic acid or CAR polypeptide;
(ii) an agent that ameliorates one or more side effects associated with administration of the cell comprising the CAR nucleic acid or CAR polypeptide; or
(iii) an agent that treats the disease associated with BCMA.

### Claim 56 (depends on 51)

The method of claim 51, wherein the cell is administered in combination with a PD-L1 inhibitor.

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59 (depends on 46)

The cell of claim 46, further expressing an inhibitory molecule that comprises a first polypeptide that comprises at least a portion of an inhibitory molecule, associated with a second polypeptide that comprises a positive signal from an intracellular signaling domain.

### Claim 60

(canceled)

### Claim 61 (depends on 55)

The method of claim 55, wherein the agent is an mTOR inhibitor and the subject is administered a low, immune enhancing, dose of an mTOR inhibitor.

### Claim 62

(canceled)

### Claim 63 (depends on 51)

The method of claim 51, wherein the cell expressing the CAR molecule is administered in combination with a cell comprising a CD19 CAR molecule.

### Claim 64 (depends on 63)

The method of claim 63, wherein the disease associated with BCMA is multiple myeloma.

### Claim 65

(canceled)

### Claim 66 (depends on 51)

The method of claim 51, wherein the cell expressing the CAR molecule is administered to the subject by one, two, three, or more separate administrations of a partial dose,
optionally wherein a first percentage of the total dose is administered on a first day of treatment, a second percentage of the total dose is administered on a subsequent (e.g., second, third, fourth, fifth, sixth, or seventh or later) day of treatment, and optionally, a third percentage (e.g., the remaining percentage) of the total dose is administered on a yet subsequent (e.g., third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or later) day of treatment,
optionally wherein 10% of the total dose of cells is administered on the first day, 30% of the total dose of cells is administered on the second day, and the remaining 60% of the total dose of cells is administered on the third day of treatment, and
optionally wherein the total cell dose comprises 1 to 5×107 or 1 to 5×108 cells.
